Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
27 February 2023 - 11:00PM
Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company
aiming to transform the lives of patients and become the world’s
foremost intracellular therapeutics company by establishing
Endosomal Escape Vehicle (EEV™) therapeutics as a new class of
medicines, today announced that Dipal Doshi, President and Chief
Executive Officer, will participate on the Neuromuscular and Bone
Corporate Panel at the Cowen 43rd Annual Health Care Conference.
The panel will be held on Wednesday, March 8, 2023 at 2:10 p.m.
Eastern Time in Boston, MA.
A live webcast will be available on the Investor Relations
section of the Company’s website at www.entradatx.com. A replay
will be available on the Entrada website for 90 days following the
event.
About Entrada Therapeutics Entrada Therapeutics
is a biopharmaceutical company aiming to transform the lives of
patients by establishing a new class of medicines, Endosomal Escape
Vehicle (EEV™)-therapeutics, to engage intracellular targets that
have long been considered inaccessible and undruggable. The
Company’s EEV therapeutics are designed to enable the efficient
intracellular delivery of a wide range of therapeutics into a
variety of organs and tissues, resulting in an improved therapeutic
index. Through its proprietary, highly versatile and modular EEV
platform, Entrada is building a robust development portfolio of
oligonucleotide-, antibody- and enzyme-based programs for the
potential treatment of neuromuscular diseases, immunology, oncology
and diseases of the central nervous system. The Company’s lead
oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for
the potential treatment of people living with Duchenne who are exon
44 and 45 skipping amenable, respectively, as well as ENTR-701
targeting myotonic dystrophy type 1 (DM1).
For more information about Entrada, please visit our
website, www.entradatx.com, and follow us
on Twitter and LinkedIn.
Investor and Media ContactKarla MacDonaldChief
Corporate Affairs Officerkmacdonald@entradatx.com
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Entrada Therapeutics (NASDAQ:TRDA)
Historical Stock Chart
From Apr 2023 to Apr 2024